You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
OTHER CONDITIONS: Do not remove from primary pack except for immediate use. For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. Oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post-menopausal bone mineral density loss. In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. For the prevention of post menopausal bone mineral density loss. When prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Lifestyle modifications and the risk benefit profile of CLIMARA should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OTHER CONDITIONS: Do not remove from primary pack except for immediate use. For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. Oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post-menopausal bone mineral density loss. In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. For the prevention of post menopausal bone mineral density loss. When prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Lifestyle modifications and the risk benefit profile of CLIMARA should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OTHER CONDITIONS: Do not remove from primary pack except for immediate use. INDICATIONS: For short term treatment of the signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. Oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. For the prevention of post menopausal bone mineral density loss. When prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Lifestyle modifications and the risk benefit profile of CLIMARA should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
Oval patch consisting pressure sensitive acrylate adhesive/drug matrix, in which active ingredient is incorporated, covered with outer polyethylene backing layer. Patch mounted split release liner.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OTHER CONDITIONS: Do not remove from primary pack except for immediate use. INDICATIONS: For short term treatment of the signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. Oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. For the prevention of post menopausal bone mineral density loss. When prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Lifestyle modifications and the risk benefit profile of CLIMARA should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
Oval patch consisting pressure sensitive acrylate adhesive/drug matrix, in which active ingredient is incorporated, covered with outer polyethylene backing layer. Patch mounted split release liner.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OTHER CONDITIONS: Do not remove from primary pack except for immediate use. INDICATIONS: For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. Oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. For the prevention of post menopausal bone mineral density loss. When prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Lifestyle modifications and the risk benefit profile of CLIMARA should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
Oval patch consisting pressure sensitive acrylate adhesive/drug matrix, in which active ingredient is incorporated, covered with outer polyethylene backing layer. Patch mounted split release liner.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OTHER CONDITIONS: Do not remove from primary pack except for immediate use. INDICATIONS: For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. Oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post menopausal bone mineral density loss. In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. For the prevention of post menopausal bone mineral density loss. When prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Lifestyle modifications and the risk benefit profile of CLIMARA should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
Oval patch consisting pressure sensitive acrylate adhesive/drug matrix, in which active ingredient is incorporated, covered with outer polyethylene backing layer. Patch mounted split release liner.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OTHER CONDITION: Do not remove from primary pack except for immediate use. For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. Oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post-menopausal bone mineral density loss. In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. For the prevention of post menopausal bone mineral density loss. When prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Lifestyle modifications and the risk benefit profile of CLIMARA should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
OTHER CONDITION: Do not remove from primary pack except for immediate use. For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. Oestradiol prevents the accelerated loss of bone density due to oestrogen deficiency and may be used for the prevention of post-menopausal bone mineral density loss. In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.,For short term treatment of signs and symptoms of oestrogen deficiency due to the menopause, whether natural or surgically induced. For the prevention of post menopausal bone mineral density loss. When prescribed solely for the prevention of post menopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who, are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. Lifestyle modifications and the risk benefit profile of CLIMARA should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing (see precautions and dosage and administration sections). In women with an intact uterus, oestrogen should always be opposed by a progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
